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Abstract
Introduction: Cryopyrin-associated periodic syndrome (CAPS) represents a spectrum of three auto-inflammatory
syndromes, familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset
multisystem inflammatory disease/chronic infantile neurological cutaneous and articular syndrome (NOMID/CINCA)
with etiology linked to mutations in the NLRP3 gene resulting in elevated interleukin-1b (IL-1b) release. CAPS is a
rare hereditary auto-inflammatory disease, which may start early in childhood and requires a life-long treatment.
Canakinumab, a fully human anti-IL-1b antibody, produces sustained selective inhibition of IL-1b. This study was
conducted to assess the efficacy, safety, and pharmacokinetics of canakinumab in the treatment of pediatric CAPS
patients.
Methods: Seven pediatric patients (five children and two adolescents) with CAPS were enrolled in a phase II,
open-label study of canakinumab in patients with CAPS. Canakinumab was administered at a dose of 2 mg/kg
subcutaneously (s.c.) (for patients with body weight ≤ 40 kg) or 150 mg s.c. (for patients with body weight >
40 kg) with re-dosing upon each relapse. The primary efficacy variable was time to relapse following
achievement of a complete response (defined as a global assessment of no or minimal disease activity and no
or minimal rash and values for serum C-reactive protein (CRP) and/or serum amyloid A (SAA) within the normal
range, < 10 mg/L).
Results: All patients achieved a complete response within seven days after the first dose of canakinumab and
responses were reinduced on retreatment following relapse. Improvements in symptoms were evident within 24
hours after the first dose, according to physician assessments. The estimated median time to relapse was 49 days
(95% CI 29 to 68) in children who received a dose of 2 mg/kg. Canakinumab was well tolerated. One serious
adverse event, vertigo, was reported, but resolved during treatment.
Conclusions: Canakinumab, 2 mg/kg or 150 mg s.c., induced rapid and sustained clinical and biochemical
responses in pediatric patients with CAPS.
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Cryopyrin-associated periodic syndrome (CAPS) comprises
a spectrum of rare inherited chronic auto-inflammatory
disorders including familial cold auto-inflammatory
syndrome (FCAS), Muckle-Wells syndrome (MWS), neo-
natal onset multisystem inflammatory disease (NOMID),
also known as chronic infantile neurological, cutaneous,
and articular syndrome (CINCA). Common characteristics
of these disorders include high-grade fever, urticarial rash,
ocular manifestations such as conjunctivitis, sensorineural
hearing loss and arthritis [1-5].
Onset of symptoms generally occurs early in life, espe-
cially in patients with the two more severe phenotypes,
MWS, and NOMID, and these disorders are associated
with developmental abnormalities and progressive worsen-
ing of clinical manifestations such as sensorineural hearing
loss and sight impairment [3-5]. In addition, the high
levels of the acute phase protein, serum amyloid A protein
(SAA) results in AA amyloidosis in approximately a quar-
ter of patients with MWS, leading to renal impairment.
Thus initiation of treatment in childhood is important for
most patients and may reduce long-term sequelae.
All three phenotypes are associated with mutations in
the NLRP3 gene encoding cryopyrin, also known as
NALP3/CIAS1 [1,6,7]. Cryopyrin is involved in the acti-
vation of interleukin (IL)-1b [8]. Mutations in NLRP3 are
associated with over-activation of caspase-1, the enzyme
which catalyses the cleavage of the precursor of IL-1b,
pro-IL-1b, to generate active IL-1b in excess [9]. This
s u g g e s t e dt h a tI L - 1 b blockade might provide effective
treatment for this rare disorder. Indeed studies with ana-
kinra, a non-glycosylated form of the endogenous antago-
nist of the IL-1 receptor, IL-1Ra, and rilonacept, which
binds to IL-1b with high affinity and thus blocks the
binding of IL-1b to its receptor, have demonstrated pro-
mising therapeutic activity in patients with CAPS
[10-12]. However, anakinra requires daily administration
which can be difficult, especially for pediatric patients,
and injections are frequently painful and can lead to
injection site reactions and rash, while rilonacept is admi-
nistered once weekly and is also frequently associated
with injection site reactions. Both substances are not
approved for the treatment of CAPS in children. There
is, therefore, a need for improved anti-IL-1b therapies for
the management of CAPS and other auto-inflammatory
conditions driven by overproduction of IL-1b.
Canakinumab is a fully human IgG1 anti-IL-1b mono-
clonal antibody that binds to human IL-1b with high
specificity and neutralizes the bioactivity of this cytokine
[13]. It has a half-life of 21 to 28 days in adults [14] and
produces rapid and sustained clinical remissions in
patients with CAPS when dosed every eight weeks [15].
This paper reports efficacy, safety, and tolerability
analysis of data of the seven pediatric patients (children
or adolescents) out of 34 patients who were enrolled in
a phase II, open-label study.
Materials and methods
Study design and intervention
This study involved patients (aged 4 to 75 years, body
weight ≥12 and < 100 kg) with documented NLRP3
mutations and a clinical picture of CAPS requiring med-
ical intervention. Patients with a very severe phenotype
receiving steroid therapy could be included if they had
r e c e i v e das t a b l ed o s ef o ra tl e a s to n ew e e kp r i o rt ot h e
screening visit. Patients on anakinra after a washout per-
iod of 15 days post screening were allowed. Any anti-IL-
1 therapy had to be discontinued before entering the
study. Female patients of child bearing age were to use
an effective method of contraception during the study
and for at least three months after the last dose.
Patients received canakinumab at a dose of 2 mg/kg
(body weight < 40 kg) or 150 mg s.c. (body weight ≥40
kg). Patients not achieving ac o m p l e t er e s p o n s ew i t h i n
seven days post initial s.c. treatment received a re-dose
of canakinumab (5 or 10 mg/kg i.v.) as a rescue medica-
tion. Treatment including the possibility of a rescue i.v.
dose was repeated upon each relapse.
The study was approved by the institutional review
board/independent ethics committee and was performed
in accordance with the Declaration of Helsinki. Written
informed consent was obtained for all participants from
parents or legal guardians and from patients, if appropriate.
Assessments
At baseline and at each study visit (post-treatment Day 1,
Day 2, Week 1 and Week 5 of each treatment period),
physicians assessed global disease activity and rash using a
5-point scale: absent, minimal, mild, moderate or severe.
Blood samples were collected for assessment of CRP and
SAA (at each study visit) and to assess hematological and
biochemical markers (baseline, post-treatment Day 1,
Day 2, Week 1, Week 5 and thereafter monthly each per-
iod) and immunogenicity (baseline, 1 day pre-dose, and
Week 5 of each period).
Efficacy assessments
The primary efficacy variable was time-to-relapse after
achieving a complete response. A complete response was
defined as a global assessment of no or minimal disease
activity and no or minimal rash, and CRP and/or SAA
levels within the normal range (< 10 mg/L for both para-
meters). Relapse was defined as having a global assessment
of disease activity of mild or greater or a global assessment
of disease activity of minimal and an assessment of rash of
mild or greater, plus CRP and/or SAA levels of > 30 mg/L.
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baseline relapse was defined by a clinical picture necessi-
tating retreatment, based on physician’s global assessment
of disease activity and rash. Secondary efficacy variables
included the proportion of patients showing a complete
response, physician assessments of disease activity,
changes in levels of CRP and SAA.
Pharmacokinetic assessments
Canakinumab concentrations were assessed in serum by
competitive ELISA assay (lower limit of quantification
(LLOQ) = 100 ng/mL). Pharmacokinetic parameters
were determined by non-compartmental analysis. IL-1b
levels were analyzed as previously described [13].
Safety assessments
Adverse events (AEs) were monitored throughout the
study. At each study visit, physicians asked patients for,
or assessed (dosing visit), any local injection site reac-
tions following s.c. administration. Other safety assess-
ments included the regular monitoring of vital signs,
hematology blood chemistry and urinalysis, and assays
for anti-canakinumab antibodies using a binding BIA-
core
® assay (Biacore International AB, Rapsgatan 7, 754
50 Uppsala, Sweden) [16]. Height and weight were mea-
sured at baseline and at the end of the study.
Statistical analysis
A Weibull gap-time frailty model was used to estimate
time-to-relapse for each dose regimen [17]. For patients
who required an additional rescue dose of canakinumab,
the dose regimen was defined as a separate group and
the time-to-relapse was calculated from the time of i.v.
rescue dose. Analyses were conducted using SAS soft-
ware, version 8.2 (SAS Institute, Cary, NC, USA).
Results
A total of 34 patients were enrolled in this phase II,
open-label study and the overall patient disposition is
presented in (Figure 1). Here we report data for seven
pediatric patients (five children aged 4 to 13 years with
MWS and two adolescents, aged 16 and 17 years, with
NOMID).
Demographics and baseline disease characteristics are
summarized in table 1. Six patients had previously
received anakinra and four had achieved a complete
response; one other patient achieved a partial response
a n dt h es i x t hp a t i e n td i dn o tr e s p o n dt oa n a k i n r a .A l l
five children received canakinumab at a dose of 2 mg/kg
s.c. (with or without a rescue dose) while the two ado-
lescents received canakinumab 150 mg s.c. All patients
received at least one dose of canakinumab and the med-
ian number of doses received was six (range 1 to 20,
including rescue doses). The total duration of exposure
to canakinumab ranged from 126 to 463 days.
Efficacy
All patients achieved a complete response to their first
dose of canakinumab and this was achieved within one
day in four patients and within seven days in the
*patient discontinued the study due to pregnancy
*
Figure 1 Patient composition.
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Page 3 of 10remaining three patients. Improvements in symptoms
were evident in all patients within 24 hours of admin-
istration of canakinumab; at baseline all patients had
moderate disease activity, while one day post-dose, dis-
ease activity was absent in four patients and minimal
in the other three. CRP and SAA levels normalized
within seven days in patients who had baseline values
above the normal range (< 10 mg/L). The levels of
CRP and SAA were maintained at normal levels in
those patients who already had normal levels at base-
line (Figure 2).
Six patients were retreated on relapse and four
achieved a second complete response within seven days
post-treatment and continued to achieve complete
responses on retreatment with single doses of canakinu-
mab on most occasions. Clinical relapses (that is,
increase in both global assessment and skin assessment
to mild or greater) were typically accompanied by an
increase in SAA and possibly CRP to greater than 30
mg/L and this pattern was observed in both children
and adolescents (Figure 3A, B). In one patient, clinical
relapses were not accompanied by increases in SAA
and/or CRP on most occasions (Figure 3C).
All five children on canakinumab 2 mg/kg s.c.
achieved a complete response within seven days post
initial dose. However, two patients with the V198M
mutation relapsed within seven days in many treatment
cycles and needed an i.v. rescue to achieve and maintain
complete response (a rescue dose was administered in
one patient after each s.c. dose and for the other patient
on three occasions out of nine treatments). In these two
patients with V198M mutation, rash and conjunctivitis
were absent; symptoms of headache, abdominal pain,
myalgia, fatigue, and fever episodes in one patient were
present, all being reversible.
The observed times to relapse for two adolescent
patients receiving 150 mg s.c. were > 125 days in one
who was discontinued after the first dose without experi-
encing a relapse and 86 days and 77 days in the second
adolescent. Those values are in agreement with the
Table 1 Demographics and baseline disease characteristics
Patient Clinical picture/NALP3mutation - Clinical symptom Weight
(kg)
CRP (mg/L) SAA (mg/L) Previous
anakinra use/
response
Physician’s global
assessment of
disease activity
1 MWS/V198M -
pyrexia, conjunctivitis, headache, abdominal pain,
arthralgia and lassitude
17.2 8.2 1.8 Yes/No* Moderate
2 MWS/E311K-
aphthae, stomach pain, fatigue, loss of energy, headache,
conjunctivitis, myalgia, fever peaks, beginning of hearing
deficit and arthralgia during night.
18.1 2.0 2.1 Yes/Partial** Moderate
3 MWS/T348M-
Vomiting
23.3 39.0
# 74.0
# Yes/Yes Moderate
4 MWS/V198M -
Low level of immunoglobulins, pyrexia, sensitivity to
infection, coldness exposed exanthema, conjunctivitis,
headache, oral aphthae, abdominal pain, myalgia and
fatigue.
24.1 0.2 2.9 Yes/Yes Moderate
5 MWS/E311K -
exanthema, myalgia, conjunctivitis, attention deficit,
headache, lack of concentration, oral aphthae, fatigue
and hearing deficiency
35.3 9.9 14.1 No Moderate
6† NOMID/T348M -
urticarial rash, hepatomegaly, pyrexia, anemia, headache,
stomach pain, malaise, nausea, fatigue, conjunctivitis,
high frequency hearing loss (1 KHz), sterile meningitis,
papilloedema, growth retardation, bilateral reduced visual
acuity, knee arthritis, back pain, myalgia, leucocytosis, and
thrombocytosis
48.6 38.9 198.0 Yes/Yes Moderate
7† NOMID/G569R -
exanthema, papillar edema, pseudo-tumor cerebri,
hearing loss, arthritis, enlarged inner and outer liquor
cavities, morphologically elevated bilateral intraocular
pressure, and an enlarged blind spot in the visual field
52.0 65.6 151.0 Yes/Yes Moderate
CRP, C-reactive protein; SAA, Serum Amyloid A.
# Local lab values.
†The two adolescent patients had MWS/NOMID.
*No response - lack of efficacy while on anakinra.
**Partial response - MWS activity despite of anakinra therapy and necessity of anakinra dosage increase.
Kuemmerle-Deschner et al. Arthritis Research & Therapy 2011, 13:R34
http://arthritis-research.com/content/13/1/R34
Page 4 of 10median time to relapse of 115 days (95% CI 94.1 to 136.4)
estimated using a Weibull analysis in the group of adults
and adolescent patients receiving 150 mg s.c. For chil-
dren receiving 2 mg/kg s.c. the estimated median time-
to-relapse was 49 (95% CI: 29.3 to 67.9) days (Table 2).
At study start, “fatigue”, which was part of the core
variables for the physicians’ global assessment, was
severe in two patients, moderate in three patients and
mild in one patient. One day post-dose “fatigue” was
absent in five patients and minimal in two patients and
this was maintained until the patient experienced the
next relapse.
PK/PD and IL-1b levels
The pharmacokinetic parameters for canakinumab are
summarized in Table 3. Peak concentrations of 7.7 to
13.6 μg/mL were achieved in children receiving doses of
2 mg/kg (total dose, 35 to 96 mg) after 2 to 7 days and
the apparent half life of canakinumab was 23 to 26 days.
The rates of IL-1b production for the five MWS patients
were 20.1 (Pt 1), 6.02 (Pt 2), 21.2 (Pt 3), 4.5 (Pt 4), and
5.8 (Pt 5) ng/day, and for the two NOMID patients 9.6
(Pt 6) and 16.7 (Pt 7) ng/day.
Safety
Canakinumab was generally well tolerated. All AEs were of
mild to moderate severity. One serious AE (SAE) was
reported, a case of vertigo (V198M, MWS) that resolved
during treatment. The most frequently reported AEs were
upper respiratory tract infections and rash (Table 4). One
patient, aged 16 years, discontinued due to positive preg-
nancy test (pregnancy test was negative at enrolment and
baseline). The pregnant adolescent was still in remission
until day 126 (time of discontinuing the study). After
discontinuation, the patient did not receive anakinra, and
prednisone treatment (40 mg at first, then 20 mg daily
based on the investigator’s assessment of disease condi-
tion) was started. Prednisone was partially effective with-
out reaching serological remission (CRP levels 10 to 30
mg/L, SAA levels 13 to 75 mg/L). The pregnancy was
uneventful and the newborn had a normal Apgar score at
birth as well as all clinical findings were unremarkable.
Injections were well tolerated. Three patients reported
mild to moderate injection-site reactions; in total in six
occasions from 54 injections. No anti-canakinumab anti-
bodies were detected in any patients.
Markers of systemic inflammation such as white blood
cell count, neutrophil count and platelet count were at
the upper limit of normal at baseline and decreased
within the first 24 hours post-dose.
Two children were anemic at baseline, and all children
had normal hemoglobin levels at the end of the study.
All other laboratory or biochemical markers (glucose,
albumin, creatinine, total protein, creatine kinase, trigly-
cerides, total cholesterol, serum glutamic oxaloacetic
transaminases, serum glutamic pyruvic transaminases,
and gamma-glutamyl transfer a s e )s h o w e dl i t t l ec h a n g e
over the course of the study. No clinically relevant
changes in diastolic and systolic blood pressure or pulse
were observed.
Over the course of the study, children gained in height
and weight. The four younger children (4 to 7 years)
who were treated on the study for 9 to 15 months
gained 2.1 to 5.6 kg and the two for whom height data
were available gained 4 cm in height. The fifth child,
aged 13, was treated in the study for 12 months and
gained 12.6 kg in weight (from 35.3 kg at study entry)
and 9 cm in height (from 155 cm at baseline).
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Figure 2 Reduction in inflammatory markers in response to a single dose of canakinumab.
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Figure 3 Response pattern in three patients: physician global assessment, physician skin assessment and CRP and SAA levels.I nt h e
upper and middle panels, the squares represent the physician’s assessment of global disease activity and rash. The shaded areas indicate absent
and mild severity. In the lower panel, the concentrations of CRP (solid line, circle) and SAA (dotted line, triangle) are presented. The shaded area
indicates a concentration of 0 to 30 mg/L. Vertical dotted lines on all panels indicate the time of re-dosing.
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The results reported here indicate that canakinumab is a
highly effective and well tolerated therapy for the treat-
ment of CAPS in pediatric patients. All patients achieved
complete clinical and biochemical responses within seven
days of receiving the first dose of canakinumab and
responses were rapidly re-induced on re-treatment after
relapse in most patients. In addition, canakinumab was
well tolerated in all patients.
This study included children who were younger than
those enrolled in the previously conducted study in CAPS
patients (31 adults and 4 children) receiving canakinumab
150 mg s.c. (body weight ≥40 kg) or 2 mg/kg s.c. (body
weight < 40 kg), administered every eight weeks [15] and
the results observed in both these studies were comparable
thus extending the observations to children as young as
four years old. In both studies, responses to canakinumab
were rapid with improvements in symptoms being
observed within 24 hours of administration of the first
dose in most patients. In addition, most patients achieved
a complete response within one week following adminis-
tration of a single dose. Responses were sustained in most
patients and were re-induced with a single dose of canaki-
numab on re-treatment.
In this study, the pharmacokinetics of canakinumab in
pediatric patients was found to be similar to that in
adults [18]. The half-life of canakinumab in children
ranged from 23 to 26 days, comparable to that
previously reported for adults with rheumatoid arthritis
(that is, 21 to 28 days) [14] and for adults with CAPS
(26 days) [13,15]. This supports every eight-week dosing
in children as in adults, which was shown to produce
sustained remissions in the phase III study which
included four children. This compares favourably with
t h ev e r ys h o r th a l f - l i f eo fa n a k i n r a( f o u rt os i xh o u r s )
[19] and half-life of 6.3 days in children and 7 days in
the adult population for rilonacept [20]. As a result of
its very short half-life, anakinra is administered once
daily while rilonacept is administered once weekly. This
need for frequent injections is an important shortcom-
ing of these medications, especially for children who
may well be afraid of needles and do not understand the
importance of their medication. The prolonged half-life
of canakinumab allows sustained remissions to be
achieved with eight-weekly dosing and, therefore, repre-
sents a major step forward in the management of this
debilitating disorder.
The estimated median time-to-relapse in this study
ranged from approximately 50 days in children receiving
a dose of 2 mg/kg s.c. to 115 days in adolescents and
adults receiving a dose of 150 mg s.c. Thus the esti-
mated time-to-relapse in children was approximately
half that for adults. This does not fit with the pharma-
cokinetic data for canakinumab reported for this study,
which show the pharmacokinetics of canakinumab in
pediatric patients to be similar to those in adults and
suggests that factors other than pharmacokinetics of
canakinumab may have contributed to the difference in
time-to-relapse. Two children with CAPS symptoms did
not have elevated CRP/SAA levels at baseline and were
diagnosed for V198M. One of these patients failed to
achieve complete response with a single s.c. dose on a
number of occasions and both patients were frequently
re-dosed (residual disease symptoms with anakinra
treatment (dose increased over the first months in one
patient and over the first year in second patient) and
frequent necessity of dosage increase to anakinra was
recorded in the medical history). V198M mutation has
Table 2 Estimated median time to relapse
Canakinumab
Dose regimen
No. of
subjects
No. of
periods
Median time to
relapse (days)
95%
confidence
interval
2 mg/kg s.c. 4 22 48.6 29.3 to 67.9
2 mg/kg s.c. +
rescue i.v.
2** 11 51.7 27.0 to 76.5
** Two subjects received rescue medication for some periods. In one out of
these two pediatric patients, data of periods in which rescue medication was
not given were analyzed with the 2 mg/kg s.c. group, while data of periods in
which rescue medication was given were analyzed separately with the 2 mg/
kg s.c. + rescue i.v. group.
Table 3 Pharmacokinetic parameters following administration of the first dose of 150 mg or 2 mg/kg canakinumab
Patient Dose (mg) Cmax (μg/mL) Tmax (d) AUC0-∞ (μgd/mL) t1/2 (d) CL/F (L/d) Vz/F (L) CL/F/wt (L/d)/kg
1 34.8 NE NE NE NE NE NE NE
2 36.0 13.6 6.96 580 25.7 0.0621 2.3 0.0034
3 46.6 7.67 2 NE NE NE NE NE
4 48.0 NE NE NE NE NE NE NE
5 71.0 12.4 2 543 23.7 0.131 4.48 0.0037
6 150.0 16.3 7.05 647 22.9 0.232 7.67 0.0048
7 150.0 10.4 2.16 NE NE NE NE NE
NE: : non-estimable.
Cmax, Maximum (peak) serum drug concentration after drug administration; Tmax, Time to reach peak or maximum concentration following drug administration;
AUC0∞, Area under the concentration-time curve from time zero to infinity; t1/2, The elimination half-life associated with the terminal slope (lz) of a semi
logarithmic concentration-time curve; CL/F, The apparent total clearance from serum; Vz/F, The apparent volume of distribution during terminal phase.
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phenotype which variably responds to increasing doses
of anti IL-1 medication [21-23]. In addition, Aksentije-
vich et al. reported a patient with a V198M variant who
did not adequately respond to anakinra treatment and
discussed that other so far unknown genetic factors may
be involved in the disease phenotype [24]. Thus, it is
possible that patients with particular mutations such as
the V198M mutation may require higher doses of cana-
kinumab or more frequent administration to maintain
their response and have contributed to the lower value
for time-to-relapse for children reported for this study.
In this study, six patients received anakinra treatment
prior to enrolment. Four were complete responders, one
patient responded partially and one patient failed to
respond to anakinra therapy. The fact that both the par-
tial and non-responder patients achieved a complete
response to canakinumab is thus encouraging.
In addition to achieving sustained clinical remissions,
most pediatric patients achieved sustained normalization
of CRP and SAA levels. This is likely to have important
implications for the long-term outcome of patients since
prolonged elevation of SAA levels is associated with the
development of AA amyloidosis which severely impairs
renal function and leads to renal failure and death if
effective therapy is not given. A recent study of patients
with a variety of inflammatory conditions reported that
the risk of death is increased 18-fold in patients with
high SAA levels (> 155 mg/dL) compared with those
with levels within the normal range [25]. In addition, a
reduction in SAA levels and a regression of amyloid
deposits was found to be associated with improved out-
comes, suggesting that normalization of SAA levels in
patients with CAPS is likely to significantly reduce their
risk of renal failure.
All children showed rapid improvement of fatigue fol-
lowing treatment, which is a great advantage for their
quality of life. Reduced fatigue leads to improved recep-
tiveness in school and is a major advantage in
development.
The data reported here indicate that canakinumab is
well tolerated in children and adolescents, as well as in
adults, as reported previously [15] and elsewhere for this
study [13]. All adverse events were mild or moderate in
severity and only one SAE, a case of vertigo that
resolved during treatment, was reported. These data
support those previously reported for the placebo-con-
trolled phase of the phase III study [15]. In addition, in
both studies [13,15] few patients reported injection site
reactions and none of these were severe. This contrasts
with anakinra and rilonacept; in studies in patients with
CAPS, approximately half of patients experienced injec-
tion-site reactions and an increased risk of infections
was observed [10,11,26]. In this study, children were
found to gain in height and weight, suggesting that
canakinumab by inhibiting the catabolic state linked to
chronic inflammation allows normal development in the
children.
The results of this study provide an important confir-
mation of the efficacy of canakinumab in children with
this rare disorder and suggest that the safety profile of
canakinumab in pediatric patients is similar to that in
adults. Safety data for canakinumab in children have
also been reported for doses of 0.5 to 9 mg/kg in chil-
dren with systemic juvenile idiopathic arthritis (SJIA)
and confirm the favourable safety profile of canakinu-
mab in children [27].
However, the results reported here are necessarily lim-
i t e ds i n c et h e ya r eb a s e do no n l ys e v e np e d i a t r i c
patients in a non controlled study. Also, the definition
of relapse remains elusive in auto-inflammatory disease
purely on clinical grounds. Although the efficacy and
safety of canakinumab for the treatment of pediatric
CAPS patients is confirmed in this study, the long-term
impact of canakinumab treatment on the course of the
disease still needs to be addressed further. In addition,
further research is warranted in CAPS patients who
have the V198M mutation to understand why they
require higher doses of canakinumab or more frequent
administration to maintain their response.
Recently, canakinumab was approved by EMA for treat-
ment of CAPS and by the FDA for FCAS and MWS in
adult and pediatric patients [28,29], giving physicians an
important new therapy for the management of this debili-
tating disorder. Early diagnosis and prompt initiation of
treatment should enable children with this rare disorder to
l i v eam o r en o r m a ll i f ea n dm a yr e d u c et h er i s ko fl o n g -
term sequelae, such as progressive loss of vision and hear-
ing and development of renal insufficiency.
Table 4 Adverse events
Patients with AEs and SAEs n (%)
SAEs* 1 (14)
AEs leading to study drug discontinuation 1**
AEs reported in ≥2 patients
Upper respiratory tract infection 5 (71)
Rash 4 (57)
Pharyngitis 3 (43)
Nasopharyngitis 3 (43)
Vomiting 3 (43)
Diarrhea 2 (29)
Rhinitis 2 (29)
Sleep disorder 2 (29)
Cough 2 (29)
Pharyngolaryngeal pain 2 (29)
Acne 2 (29)
*One patient experienced vertigo, considered as a SAE, which resolved during
treatment. ** pregnancy.
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Canakinumab is an effective, well tolerated therapy for
pediatric patients with CAPS.
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